The tumor suppressor NKX3.1 is targeted for degradation by DYRK1B kinase

Molecular Cancer Research

Volumn 13, Issue 5, 2015, Pages 913-922

  Song, Liang Nian ^a   Silva, Jose ^b   Koller, Antonius ^a   Rosenthal, Andrew ^c   Chen, Emily I ^a   Gelmann, Edward P ^a  

^a Department of Medicine   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUAL SPECIFICITY TYROSINE REGULATED KINASE 1B; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN NKX3.1; UNCLASSIFIED DRUG; DYRK KINASE; HOMEODOMAIN PROTEIN; NKX3-1 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; TRANSCRIPTION FACTOR;

ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE OVEREXPRESSION; HALF LIFE TIME; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LNCAP CELL LINE; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; STEADY STATE; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; HIGH THROUGHPUT SCREENING; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

CELL LINE, TUMOR; GENES, TUMOR SUPPRESSOR; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HOMEODOMAIN PROTEINS; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84942326104     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0680     Document Type: Article

References (32)

1. Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, et al. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p21-22. Cancer Res 1996; 56:2411-6.
2. Swalwell JI, Vocke CD, Yang Y, Walker JR, Grouse L, Myers SH, et al. Determination of a minimal deletion interval on chromosome band 8p21 in sporadic prostate cancer. Genes Chromosomes Cancer 2002;33:201-5.
3. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, et al. Punctuated evolution of prostate cancer genomes. Cell 2013;153:666-77.
4. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
5. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Norton CR, et al. Roles for Nkx3.1 in prostate development and cancer. Genes and Development 1999;13:966-77.
6. Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, Desai N, Wang Y, Hayward SW, et al. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 2002;62:2999-3004.
7. Wang X, Kruithof-de JM, Economides KD, Walker D, Yu H, Halili MV, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009;461:495-500.
8. Asatiani E, Huang WX, Wang A, Rodriguez OE, Cavalli LR, Haddad BR, et al. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res 2005;65:1164-73.
9. Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000;60:6111-5.
10. Markowski MC, Bowen C, Gelmann EP. Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1. Cancer Res 2008;68:6896-901.
11. Becker W, Weber Y, Wetzel K, Eirmbter K, Tejedor FJ, Joost HG. Sequence characteristics, subcellular localization, and substrate specificity of DYRKrelated kinases, a novel family of dual specificity protein kinases. J Biol Chem 1998;273:25893-902.
12. Zou Y, Ewton DZ, Deng X, Mercer SE, Friedman E. Mirk/dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288. J Biol Chem 2004;279:27790-8.
13. Jin K, Ewton DZ, Park S, Hu J, Friedman E. Mirk regulates the exit of colon cancer cells from quiescence. J Biol Chem 2009;284:22916-25.
14. Gao J, Zhao Y, Lv Y, Chen Y, Wei B, Tian J, et al. Mirk/Dyrk1B mediates G0/ G1 to S phase cell cycle progression and cell survival involving MAPK/ERK signaling in human cancer cells. Cancer Cell Int 2013;13:2.
15. Hu J, Deng H, Friedman EA. Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition. Int J Cancer 2013;132: 2258-69.
16. Ewton DZ, Hu J, Vilenchik M, Deng X, Luk KC, Polonskaia A, et al. Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells. Mol Cancer Ther 2011;10:2104-14.
17. Miyata Y, Nishida E. DYRK1A binds to an evolutionarily conserved WD40-repeat protein WDR68 and induces its nuclear translocation. Biochim Biophys Acta 2011;1813:1728-39.
18. Birmingham A, Selfors LM, Forster T, Wrobel D, Kennedy CJ, Shanks E, et al. Statistical methods for analysis of high-throughput RNA interference screens. Nat Methods 2009;6:569-75.
19. Soppa U, Schumacher J, Florencio OV, Pasqualon T, Tejedor FJ, Becker W. The Down syndrome-related protein kinase DYRK1A phosphorylates p27 (Kip1) and Cyclin D1 and induces cell cycle exit and neuronal differentiation. Cell Cycle 2014;13:2084-100.
20. Gockler N, Jofre G, Papadopoulos C, Soppa U, Tejedor FJ, Becker W. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS J 2009;276:6324-37.
21. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, et al. Mutations of the gene encoding the protein kinase Atype I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000;26:89-92.
22. Ju JH, Maeng JS, Zemedkun M, Ahronovitz N, Mack JW, Ferretti JA, et al. Physical and functional interactions between the prostate suppressor homeoprotein NKX3.1 and serum response factor. J Mol Biol 2006; 360:989-99.
23. Rosenthal AS, Tanega C, Shen M, Mott BT, Bougie JM, Nguyen DT, et al. Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk). Bioorg Med Chem Lett 2011;21:3152-8.
24. Timm T, von Kries JP, Li X, Zempel H, Mandelkow E, Mandelkow EM. Microtubule affinity regulating kinase activity in living neurons was examined by a genetically encoded fluorescence resonance energy transfer/ fluorescence lifetime imaging-based biosensor: inhibitors with therapeutic potential. J Biol Chem 2011;286:41711-22.
25. BowenC, Gelmann EP.NKX3.1 activates cellular response toDNAdamage. Cancer Res 2010;70:3089-97
26. Bowen C, Ju JH, Lee JH, Paull TT, Gelmann EP. Functional activation of ATM by the prostate cancer suppressor NKX3.1. Cell Rep 2013;4:516-29.
27. Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, Shen MM, et al. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A 2002; 99:2884-9.
28. Friedman E. Mirk/Dyrk1B in cancer. J Cell Biochem 2007;102:274-9.
29. Deng X, Mercer SE, Shah S, Ewton DZ, Friedman E. The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G(0) by Mirk/dyrk1B kinase. J Biol Chem 2004;279:22498-504.
30. Deng X, Ewton DZ, Friedman E. Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species. Cancer Res 2009;69:3317-24.
31. Becker W. Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control. Cell Cycle 2012;11:3389-94.
32. Coombs TC, Tanega C, Shen M, Wang JL, Auld DS, Gerritz SW, et al. Smallmolecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: Development of chemical probe ML315. Bioorg Med Chem Lett 2013;23:3654-61.